RPRX | Royalty Pharma plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	25.40 - 26.10
52 Week Range	24.05 - 31.66
Beta	0.45
Implied Volatility	28.03%
IV Rank	33.89%
Day's Volume	2,207,037
Average Volume	2,792,504
Shares Outstanding	444,302,000
Market Cap	11,440,776,500
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-06-16

Valuation
Profitability
Growth
Health
P/E Ratio	10.14
Forward P/E Ratio	6.40
EPS	2.54
1YR Price Target	48.50
Dividend Yield	3.25%
Dividend Per Share	0.84
Dividend ExDate	2023-08-17
Dividend PayDate	2023-09-15
Employees	75
Country	USA
Website	RPRX

Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.

RPRX's peers: ADPT, PRME, RPHM, DNA, OCEA, VECT, KNTE, IKNA, ASND, APLS, BGNE, AKRO, BPMC, IOVA, CVAC, MDGL, MRTX, ISEE, AMLX, KRTX, DAWN

*Chart delayed

Analyzing fundamentals for RPRX we got that it has average fundamentals where Valuation is considered to be significantly undervalued, Profitability is wealthy, Growth is good and Health is weak. For more detailed analysis please see RPRX Fundamentals page.

Watching at RPRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on RPRX Technicals page.